Because less than one-third of DMD cases in Mexico are expected to achieve a “definitive” dystrophinopathy diagnosis based on DNA or immunodetection analysis [14], it would be useful to develop an affordable, non-invasive and first-line diagnostic tool that can be used to identify the underlying genetic etiology of clinically suspected muscular dystrophy in Mexican patients without a DMD gene deletion identified by the conventional multiplex polymerase chain reaction (mPCR) method. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.